The efficacy and safety of axitinib , a potent and selective second-generation inhibitor of vascular endothelial growth factor receptors @ , @ , and @ in combination with pemetrexed and cisplatin was evaluated in patients with advanced non-squamous non-small-cell lung cancer ( NSCLC ) .